Show simple item record

 
dc.contributorDepartament de Salut
dc.contributor.authorPrograma d'Harmonització Farmacoterapèutica
dc.date.accessioned2022-04-13T08:58:05Z
dc.date.available2022-04-13T08:58:05Z
dc.date.issued2021-10-21
dc.identifier.citationPrograma d'Harmonització Farmacoterapèutica. Givosiran per al tractament de la porfíria hepàtica aguda. Barcelona: Servei Català de la Salut; 2021.
dc.identifier.urihttps://hdl.handle.net/11351/7365
dc.descriptionGivosiran; Acute hepatic porphyria; Minority disease
dc.description.abstractPorphyrias are a group of metabolic diseases caused by a loss of functionality in the enzymes involved in the biosynthesis of the heme group. They are classified according to the main clinical manifestations (neurological or cutaneous) and the tissue where the enzymatic alteration occurs (liver or bone marrow). Thus, those that affect the liver are called hepatic porphyria
dc.language.isocat
dc.publisherServei Català de la Salut
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subjectPorfíria - Tractament
dc.subject.meshPorphyrias, Hepatic
dc.subject.mesh/drug therapy
dc.subject.meshOutcome and Process Assessment (Health Care)
dc.titleGivosiran per al tractament de la porfíria hepàtica aguda
dc.typeinfo:eu-repo/semantics/report
dc.subject.decsporfirias hepáticas
dc.subject.decs/farmacoterapia
dc.subject.decsevaluación de resultados y procesos (atención a la salud)
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record